Ori’s IRO® platform. The IIT is aiming to evaluate ImmuXell’s TCR-T therapy in patients with solid tumors harboring KRAS G12V mutations, including those with colorectal cancer, pancreatic cancer, and lung cancer — all among the deadliest and most...
project represents a major government-led initiative with a total investment of approximately US$260 million over the next 10 years. Under the framework, VECOL has been designated by the Colombian government as the lead implementing entity...
genetically confirmed HoFH completed the 72-week, open-label, extension study, with mean and absolute LDL-C reductions of 19.1% and 1.44 mmol/L (55.7 mg/dL), respectively, at the 72-week primary endpoint. At week 72, mean ApoB was reduced by 12.7%...
The 9th Annual Digi-Tech Pharma & AI conference, a premier Pharmaceutical Technology Conference, brings with it even more interactive sessions, expert speakers, senior professionals and decision makers from leading pharma, bio-tech and healthcare...
and sensitivity to light and sound. Migraine affects one in seven people and is a leading cause of disability worldwide.1 Approximately 11% of the population in Korea currently lives with migraine, a figure that may be underestimated.1,2 Despite...
therapy beyond five years.2,3 More information on these findings will be presented at the 2026 ASCO Annual Meeting on June 1. The data come from a new analysis of the ongoing BCI Registry Study, which evaluates how physicians incorporate prognostic...
a biotechnology company developing first-in-class therapies targeting cancer stem cells, announced that its second ADAR1p150 protein crystallization experiment has successfully launched aboard the SpaceX CRS-34 commercial resupply mission to the...
(PEF) therapies for oncology and chronic lung disease, today announced that it received U.S. Food and Drug Administration 510(k) clearance for the Aliya® EX Generator for surgical ablation of soft tissue. The Aliya EX Generator expands the Aliya...
announced that Peter Menziuso has been named executive vice president and president, BD Interventional, effective June 1. Menziuso brings more than 30 years of global healthcare leadership experience and a strong track record of driving growth...
that re-induction with ADSTILADRIN® (nadofaragene firadenovec-vncg) resulted in complete responses (CR) in approximately 31% (4/13) of patients with high-risk Bacillus Calmette-Guérin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC)...
the skin's intrinsic longevity pathways to visibly restore firmness, smoothness, and overall skin health." clinical claims 100% saw skin that looked lifted, deeply replenished, and more even-toned* *Results after 8 weeks. Based on a consumer...
Pathobiology 2026 – May 16-19, 2026, in Fort Myers, Florida. Similar to the past two Annual Meetings, Pathobiology 2026 will be a stand-alone meeting that will leverage our society’s unique strengths in the understanding of cellular and molecular...
and adjuvant treatment of patients with HER2-positive early breast cancer based on results from the DESTINY-Breast11 and DESTINY-Breast05 Phase III trials, respectively. In the neoadjuvant setting, ENHERTU followed by a taxane, trastuzumab, and...
cancer has muscle-invasive disease, where the tumor invades the muscle wall of the bladder, without distant metastases.1,2 As many as 50% of patients are ineligible for cisplatin-based chemotherapy due to impaired renal function or...
SCRN, FAHA, FNCS, FCCM, will speak as part of NeurOptics' in-booth clinical education programming at AACN NTI 2026, May 17–20, in San Diego. NeurOptics will be exhibiting in Booth #1616. Olson will present "Evidence-Based Practice in Pupillometry"...
systems, influencing metabolism, immune function, and physical performance. Tetraselmis chuii was first identified in the 1950s and has long been used in aquaculture due to its rich nutritional profile, "We invested more than 20 years in developing...
to patients living with conditions such as obesity, diabetes and cardiovascular disease. Obesity alone contributes nearly $173 billion in annual medical costs, while more than two in five U.S. adults have prediabetes — most of whom are unaware of...
following her role as Chief Commercial Officer at TAPI, a division of Teva, where she led a global organization spanning 15 countries and was responsible for executing commercial strategy, accelerating growth initiatives, building strong...
for the treatment of adults with advanced, unresectable or metastatic cholangiocarcinoma harboring a neuregulin 1 (NRG1) gene fusion with disease progression on or after prior systemic therapy. This marks the first targeted therapy approved...
in partnership with the board of directors. McBrayer will remain president and CEO until Rushdy assumes the role on May 18. “Patrick joined Miach at a pivotal moment, as we were accelerating commercialization of the BEAR Implant,” said Joyce Erony,...